#1 Clinical Trials Search in Europe

A study of pembrolizumab, cetuximab, and MK-1084 for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations

2 1 1 1

What is this study about?

This study is for people with Nonsquamous Non-small Cell Lung Cancer, a type of lung cancer that does not involve certain specific cell shapes, which has spread or is at an advanced stage. The research focuses on patients who specifically have a KRAS G12C mutation, which is a change in the genetic code of the cancer cells. The purpose of the study is to evaluate the safety and effectiveness of different combinations of new treatments.

Participants may receive several different medications. These include cetuximab, which is given through an intravenous infusion, a method of delivering medicine directly into a vein, and MK-1084, which is taken as a pill. Other medications being studied include pembrolizumab, also given by intravenous infusion. Some people may receive a combination of these new drugs, while others may receive standard treatments like carboplatin or pemetrexed.

During the study, different groups of participants will be assigned to receive different combinations of these medicines to see which ones work best. The process involves regular monitoring to see how the body reacts to the treatments and how the cancer changes over time.

Who Can Join the Study?

  • You must have a confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC), which means the lung cancer is not the small cell type and has spread or grown significantly.
  • Your tumor must show a specific genetic change called a KRAS G12C mutation, which is found either in a piece of the tumor tissue or in circulating tumor DNA (ctDNA), which is small pieces of genetic material from the cancer found in the blood.
  • You must be able to provide a sample of the tumor, either from archival tissue (older samples already stored) or through a new biopsy (taking a small piece of the tumor using a needle or surgical cut) from an area that has not been treated with radiation.
  • Any adverse events (unwanted side effects) from previous cancer treatments must have improved to a mild level or back to your normal state.
  • If you have neuropathy (nerve damage that causes numbness or tingling) or endocrine-related side effects (problems with hormones), they must be mild or well-managed with hormone replacement therapy.
  • If you have human immunodeficiency virus (HIV), it must be well-controlled using antiretroviral therapy (ART), which is medication used to manage the virus.
  • If you have hepatitis B (HBV), the amount of virus in your blood must be undetectable, and if you test positive for the surface antigen (HBsAg), you must have been taking antiviral medicine for at least 4 weeks.
  • If you have hepatitis C (HCV), the amount of virus in your blood must be undetectable.

Who Cannot Join the Study?

  • You cannot participate if you have small cell lung cancer, which is a specific and aggressive type of lung cancer.
  • You cannot participate if you have a weakened immune system, known as immunodeficiency, or if you are taking long-term steroid therapy (medicines that reduce inflammation) at a high dose.
  • You cannot participate if you are taking any other immunosuppressive therapy, which are medicines that lower your body’s ability to fight infections, within 7 days before the study starts.
  • You cannot participate if you have another type of cancer that is currently growing or has needed treatment in the last 3 years.
  • You cannot participate if you have cancer that has spread to the central nervous system (the brain and spinal cord) or if you have carcinomatous meningitis, which is when cancer cells spread to the protective layers covering the brain and spinal cord.
  • You cannot participate if you have an autoimmune disease, which is a condition where the body’s immune system attacks its own healthy cells, that required systemic medicine in the last 2 years.
  • You cannot participate if you have or have had pneumonitis or interstitial lung disease, which are conditions involving inflammation or scarring of the lung tissue, that required steroids.
  • You cannot participate if you have a history of receiving a stem cell transplant or a solid organ transplant (such as a kidney or liver transplant).
  • You cannot participate if you have not fully recovered from a major surgery or if you are currently having problems related to a recent surgery.
  • You cannot participate if you have HIV infection along with a history of Kaposi’s sarcoma or Multicentric Castleman’s Disease, which are rare types of cancer or swelling of lymph nodes.
  • You cannot participate if you have inflammatory bowel disease, such as Crohn’s disease or ulcerative colitis, that requires medicine to calm the immune system.
  • You cannot participate if you have serious heart or blood vessel problems, such as congestive heart failure (when the heart cannot pump enough blood), unstable angina (chest pain), myocardial infarction (a heart attack), or an irregular heartbeat called arrhythmia.
  • You cannot participate if your heart rhythm shows a specific electrical delay called a prolonged QT interval.
  • You cannot participate if you have had heart or blood vessel issues within the 6 months before the study begins.
  • You cannot participate if you have already received other systemic anticancer treatments for advanced or spreading non-small cell lung cancer (NSCLC).
  • You cannot participate if you stopped previous immunotherapy (treatment that helps the immune system fight cancer) due to severe immune-related adverse events, which are side effects where the immune system attacks healthy organs.
  • You cannot participate if you stopped immunotherapy due to myocarditis (inflammation of the heart muscle) or recurring lung inflammation.
  • You cannot participate if you have previously used a medicine that specifically targets the KRAS gene.
  • You cannot participate if you have received anticancer treatment very recently and have not yet recovered from adverse events, which are side effects or medical problems caused by the treatment.
  • You cannot participate if you have had high-dose radiation therapy to the lungs within the 6 months before the study starts.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Kuopio University Hospital Kuopio Finland
Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie Koszalin Poland

Other Sites

Site Name City Country Status
Vaasa Central Hospital Vaasa Finland
Turku University Hospital Turku Finland
Hospital Universitario Quironsalud Madrid Pozuelo De Alarcon Spain
Deventer Ziekenhuis Deventer The Netherlands
Fondazione I.R.C.C.S. Istituto Neurologico Besta Milan Italy
Lrxge Ubgapazpitgb Mdbcelb Cbgwnfs (yojkj Leiden The Netherlands
Aypyxck Oubmzrqrtni S Gisdwwgx Abmodahqng Rome Italy
Ilurywqt Rgkfkerqf Pbf Lh Sxxkdh Dvb Toqojp Duhn Ajzkvkz Iusu Syihyg Meldola Italy
Hsgdjmrc Ugmukoklmg Coowdpr Hzhglyos Helsinki Finland
Nqotmavw Ixsozgac Onyvojcdz Ifb Mtzxg Sllfnhxyxreoxfdkxihgldhwxvfi Ihhnkxpz Bgirjtiw Cracow Poland
Ukzzifuzulwhdk Casqbjt Kahkhigda Gdansk Poland

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Finland Finland
Recruiting
14.01.2026
Italy Italy
Recruiting
14.01.2026
Poland Poland
Not yet recruiting
14.01.2026
Spain Spain
Recruiting
14.01.2026
The Netherlands The Netherlands
Recruiting
14.01.2026

Trial locations

Investigated drugs:

Cetuximab is an investigational medicine given through an IV infusion that works by targeting specific proteins on the surface of cancer cells to help stop them from growing.

MK-1084 is an investigational medicine taken as a pill that is being studied for its ability to target specific genetic mutations in cancer cells.

Pembrolizumab is an investigational immunotherapy given through an IV infusion that helps the body’s own immune system recognize and attack cancer cells.

Carboplatin is a medication given through an IV infusion that is used as a comparison treatment to help slow or stop the growth of cancer cells.

Pemetrexed is a medication given through an IV infusion that is used as a comparison treatment to interfere with the way cancer cells grow and divide.

Non-small cell lung cancer – This is a type of lung cancer that does not start in the cells that produce mucus. It is characterized by the uncontrolled growth of abnormal cells in the lung tissue. In certain cases, the cancer is driven by a specific genetic mutation known as KRAS G12C. As the disease progresses, the cancer cells may spread from the original site in the lung to other parts of the body. This spread is referred to as metastatic disease.

Trial ID:
2025-521939-36-00
Protocol code:
MK-3475-01J
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study of MK-1084 plus durvalumab in patients with locally advanced unresected KRAS G12C‑mutated non‑small cell lung cancer after chemoradiotherapy

    Recruiting

    3 1 1
    Investigated drugs:
    France Germany Greece Italy The Netherlands Poland +1

  • Zongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Spain